Madrigal Pharmaceuticals
MDGL · NASDAQ
$467.54+$20.45 (+4.57%)TodayMarket closed ·
Prev close $447.09
EPS: actual vs estimate
Beat the estimate in 6 of the last 8 quarters, by 29.1% on average
Next report: , before the market opens
- Quarter
- Q3 FY26
- EPS estimate
- -$1.07
- Revenue estimate
- $405.03M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$2.62 | -$1.99 | +24.0% |
| Q1 FY26 | -$4.11 | -$3.25 | +20.9% |
| Q4 FY25 | -$0.6872 | -$2.57 | −274.0% |
| Q3 FY25 | -$2.12 | -$4.96 | −133.6% |
| Q2 FY25 | -$3.71 | -$1.90 | +48.8% |
| Q1 FY25 | -$3.84 | -$3.32 | +13.5% |
| Q4 FY24 | -$4.33 | -$2.71 | +37.4% |
| Q3 FY24 | -$7.05 | -$4.92 | +30.2% |
Earnings calls
- 12th Annual Cantor Fitzgerald Global Healthcare Conference
- Canaccord Genuity's 46th Annual Growth Conference
- MDGL - Earnings call Q2 2026
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- MDGL - Earnings call Q1 2026
- MDGL - Earnings call Q4 2025
- 44th Annual J.P. Morgan Healthcare Conference
- Jefferies London Healthcare Conference 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.